Document Mentions (6 shared documents)

EFTA00148445

2 mentions1 same-page

Page ?Same page

solidify its position as a go-to medicine for Covid-19 patients even as other drugs for the disease begin to reach the market." USA Today (10/22, Rice, 10.31M) reports that Gilead Chief Medical Officer Merdad Parsey said the drug has approvals or authorizations in around 50 countries. EFTA00148471

rketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug is approved for use in "people at least 12 years old and weighing at least 88 pounds (40 kilograms) who are hospitalized for a coronaviru

EFTA00148578

2 mentions1 same-page

Page ?Same page

888K) reports Reps. Ted Lieu (D-CA) and Kathleen Rice (D-NY) "urged FBI Director Christopher Wray to op

d the supply, looking at lowering the required dosage and extracting more doses from the supplies they have." The Times adds that scientists at the National Institutes of Health and Moderna "are analyzing data to see if they can double the supply of the company's coronavirus vaccine by cutting doses in half" as part of a "lo

EFTA02686105

2 mentions1 same-page

Page ?Same page

r S. Banga Operating Partner Clayton, Dubilier & Rice LLP United Kingdom Britt D. Banks Adjunct Prof

Kong SAR United Kingdom USA Israel USA USA United Kingdom United Kingdom Switzerland Switzerland South Africa United Kingdom DuPont USA National Institutes of Health USA YCAB (Yayasan Cinta Anak Indonesia Bangsa) Foundation Forrester Research Inc. USA Compagnie Financiere Switzerland Tradition Vodafone G